GlassScriptPhysician profile
Darrick W Neibaur
NPI 1134375918
$35,747.96
in general payments reported to CMS, 2019-2025
37 companies · $3,608 in 2025
The $3,608 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,118 · 2020: $4,406 · 2021: $3,314 · 2022: $11K · 2023: $4,282 · 2024: $2,955 · 2025: $3,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,147 · Travel and Lodging: $1,010 · Consulting Fee: $1,000 · Long Term Medical Supply Or Device Loan: $660 · Honoraria: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,147.44 |
| Travel and Lodging | $1,009.85 |
| Consulting Fee | $1,000.00 |
| Long Term Medical Supply Or Device Loan | $660.00 |
| Honoraria | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $14,293.35 | 2019-2025 | Cequa |
| Alcon Vision LLC | $3,252.46 | 2019-2025 | Hydrus Microstent, Clareon, Argos |
| Bausch & Lomb Americas INC. | $2,230.07 | 2022-2025 | Stellaris Elite, Teneo, Envista Aspire Iol |
| Abbvie INC. | $2,025.31 | 2022-2025 | |
| Ivantis, INC | $1,566.42 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $1,416.11 | 2019-2022 | |
| Glaukos Corporation | $1,373.87 | 2019-2025 | Idosetr, Istent Infinite Trabecular Micro-Bypass System Model Is3, Idose |
| Carl Zeiss Meditec USA, INC. | $1,331.44 | 2022 | |
| Sight Sciences, INC. | $870.78 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $862.96 | 2019-2023 | Lipiflow System Activator (Disposable) |
| Rxsight INC | $826.73 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $713.28 | 2020-2021 | |
| Allergan, INC. | $702.52 | 2019-2022 | |
| Ocular Therapeutix, INC. | $672.47 | 2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $500.08 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $423.88 | 2019-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Oyster Point Pharma, INC. | $376.44 | 2022-2025 | Tyrvaya |
| Ani Pharmaceuticals, INC. | $369.60 | 2023-2025 | Purified Cortrophin Gel |
| Aerie Pharmaceuticals, INC. | $315.11 | 2019-2021 | |
| Ellexiscience | $285.57 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $247.91 | 2024-2025 | Xdemvy |
| Microsurgical Technology, INC. | $160.06 | 2022 | |
| Astellas Pharma US INC | $142.05 | 2023 | |
| Apellis Pharmaceuticals, INC. | $137.33 | 2023-2025 | Syfovre |
| Melinta Therapeutics, LLC | $123.86 | 2023 | Kimyrsa |
| Mallinckrodt Hospital Products INC. | $122.61 | 2022-2025 | Acthar |
| Horizon Therapeutics Plc | $86.95 | 2022-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $84.53 | 2022 | |
| Dompe US, INC. | $55.85 | 2019-2024 | Oxervate |
| Lensar, INC. | $32.34 | 2019-2025 | Lensar Laser System |
| Halozyme INC | $28.18 | 2022-2024 | Hylenex Recombinant |
| Genentech USA, INC. | $26.43 | 2025 | Vabysmo |
| Harrow Eye, LLC | $23.04 | 2025 | Vevye |
| Eyepoint US, INC. | $19.09 | 2021 | |
| Kedrion Biopharma, INC. | $18.50 | 2025 | Rhogam Ultra-Filtered Plus, Koate, Gammaked |
| Biotissue Holdings INC. | $16.00 | 2025 | |
| Amgen INC. | $14.78 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrick Neibaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.